Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Drechsler, C; Delgado, G; Wanner, C; Blouin, K; Pilz, S; Tomaschitz, A; Kleber, ME; Dressel, A; Willmes, C; Krane, V; Krämer, BK; März, W; Ritz, E; van Gilst, WH; van der Harst, P; de Boer, RA.
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies.
J Am Soc Nephrol. 2015; 26(9):2213-2221 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Maerz Winfried
Pilz Stefan
Tomaschitz Andreas
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 3
| | |
Abstract:
Galectin-3 has been linked to incident renal disease, experimental renal fibrosis, and nephropathy. However, the association among galectin-3, renal function, and adverse outcomes has not been described. We studied this association in two large cohorts of patients over a broad range of renal function. We measured galectin-3 concentrations in baseline samples from the German Diabetes mellitus Dialysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2579 patients with coronary angiograms). Patients were stratified into three groups: eGFR of ≥90 ml/min per 1.73 m(2), 60-89 ml/min per 1.73 m(2), and <60 ml/min per 1.73 m(2). We correlated galectin-3 concentrations with demographic, clinical, and biochemical parameters. The association of galectin-3 with clinical end points was assessed by Cox proportional hazards regression within 10 years (LURIC) or 4 years (4D) of follow-up. Mean±SD galectin-3 concentrations were 12.8±4.0 ng/ml (eGFR≥90 ml/min per 1.73 m(2)), 15.6±5.4 ng/ml (eGFR 60-89 ml/min per 1.73 m(2)), 23.1±9.9 ng/ml (eGFR<60 ml/min per 1.73 m(2)), and 54.1±19.6 ng/ml (dialysis patients of the 4D study). Galectin-3 concentration was significantly associated with clinical end points in participants with impaired kidney function, but not in participants with normal kidney function. Per SD increase in log-transformed galectin-3 concentration, the risks of all-cause mortality, cardiovascular mortality, and fatal infection increased significantly. In dialysis patients, galectin-3 was associated with the combined end point of cardiovascular events. In conclusion, galectin-3 concentrations increased with progressive renal impairment and independently associated with cardiovascular end points, infections, and all-cause death in patients with impaired renal function. Copyright © 2015 by the American Society of Nephrology.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Cardiovascular Diseases - mortality
Cause of Death -
Diabetic Nephropathies - blood
Diabetic Nephropathies - mortality
Diabetic Nephropathies - therapy
Female -
Follow-Up Studies -
Galectin 3 - blood
Galectin 3 - epidemiology
Glomerular Filtration Rate -
Humans -
Infection - mortality
Male -
Middle Aged -
Renal Dialysis -
Renal Insufficiency, Chronic - blood
Renal Insufficiency, Chronic - mortality
Renal Insufficiency, Chronic - therapy
Severity of Illness Index -

© Meduni Graz Impressum